Literature DB >> 9823778

Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer.

K Sato1, R Sasaki, Y Ogura, N Shimoda, H Togashi, K Terada, T Sugiyama, H Kakinuma, O Ogawa, T Kato.   

Abstract

We investigated expression of the vascular endothelial growth factor (VEGF) gene and its receptor gene (flt-1) in 30 patients with transitional cell carcinoma (TCC) of the urinary bladder by Northern blot hybridization analysis. The VEGF transcript was observed in all of the tumors and the normal mucosae. Of the 20 tumors in which a comparative study was done, eight (40.0%) overexpressed the gene with a tumor versus normal ratio of equal to and greater than 3.0. Invasive TCCs expressed significantly more VEGF gene than superficial TCCs. Cytoplasm of tumor cells was positively stained by immunohistochemistry with an anti-VEGF monoclonal antibody, while the intratumoral endothelial cells and the vascular smooth muscle cells were weakly positive for the staining. TCCs, normal mucosae and human umbilical endothelial cells expressed flt-1 gene, while leucocytes from peripheral blood did not. The expression level of flt-1 gene significantly correlated with that of the VEGF gene in the tumor. These results indicate that the VEGF gene is frequently overexpressed in TCC of the urinary bladder, especially in muscle invasive tumors, and that a paracrine system including VEGF and flt-1 exists between the TCC cells and the adjacent endothelial cells so as to regulate the angiogenesis in this tumor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823778     DOI: 10.1620/tjem.185.173

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  7 in total

1.  Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.

Authors:  Patricia M LoRusso; Smitha Krishnamurthi; Hagop Youssoufian; Nancy Hall; Floyd Fox; Aruna Dontabhaktuni; Dmitri Grebennik; Scot Remick
Journal:  Invest New Drugs       Date:  2013-08-01       Impact factor: 3.850

Review 2.  Molecular pathways in bladder cancer.

Authors:  Stephen G Williams; John P Stein
Journal:  Urol Res       Date:  2004-11-13

Review 3.  Growth factors and receptors as prognostic markers in urothelial carcinoma.

Authors:  Peter C Black; Colin P N Dinney
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

Review 4.  VEGF targets the tumour cell.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

5.  Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Authors:  Daniel P Petrylak; Ronald de Wit; Kim N Chi; Alexandra Drakaki; Cora N Sternberg; Hiroyuki Nishiyama; Daniel Castellano; Syed A Hussain; Aude Fléchon; Aristotelis Bamias; Evan Y Yu; Michiel S van der Heijden; Nobuaki Matsubara; Boris Alekseev; Andrea Necchi; Lajos Géczi; Yen-Chuan Ou; Hasan Senol Coskun; Wen-Pin Su; Jens Bedke; Georgios Gakis; Ivor J Percent; Jae-Lyun Lee; Marcello Tucci; Andrey Semenov; Fredrik Laestadius; Avivit Peer; Giampaolo Tortora; Sufia Safina; Xavier Garcia Del Muro; Alejo Rodriguez-Vida; Irfan Cicin; Hakan Harputluoglu; Scott T Tagawa; Ulka Vaishampayan; Jeanny B Aragon-Ching; Oday Hamid; Astra M Liepa; Sameera Wijayawardana; Francesca Russo; Richard A Walgren; Annamaria H Zimmermann; Rebecca R Hozak; Katherine M Bell-McGuinn; Thomas Powles
Journal:  Lancet Oncol       Date:  2019-11-18       Impact factor: 41.316

6.  Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).

Authors:  Andrea Necchi; Hiroyuki Nishiyama; Nobuaki Matsubara; Jae-Lyun Lee; Daniel P Petrylak; Ronald de Wit; Alexandra Drakaki; Astra M Liepa; Huzhang Mao; Katherine Bell-McGuinn; Thomas Powles
Journal:  BMC Urol       Date:  2020-11-07       Impact factor: 2.264

7.  The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.

Authors:  P Manders; L V A M Beex; V C G Tjan-Heijnen; J Geurts-Moespot; T H Van Tienoven; J A Foekens; C G J Sweep
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.